Señales en vivo de IVVD | Maximiza tus Ganancias con Getagraph.com

COMPRAR 122725 min ago

@ $4.03

Emitido: 14 feb 2024 @ 15:29

Retorno: -39.95%

Señal anterior: feb 13 - 14:11

Señal anterior: Vender

Retorno: 1.26 %

Live Chart Being Loaded With Signals

Commentary (9 may 2024 @ 16:00):

Stats
Volumen de hoy	232 514
Volumen promedio	735 496
Capitalización de mercado	288.51M
EPS	$0 ( 2024-03-28 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.340
ATR14	$0.00300 (0.12%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-24	Green Julie	Buy	240 000	Stock Option (Right to Buy)
2024-01-24	Green Julie	Sell	110 700	Stock Option (Right to Buy)
2024-01-24	Green Julie	Sell	97 500	Stock Option (Right to Buy)
2024-01-24	Green Julie	Sell	160 000	Stock Option (Right to Buy)
2024-01-19	Adimab, Llc	Sell	5 000 000	Common Stock

INSIDER POWER
7.18
Last 36 transactions
Buy: 9 419 589 \| Sell: 5 442 000

Volumen Correlación

Largo: -0.50 (neutral)

Corto: 0.15 (neutral)

Signal:(42.501) Neutral

Invivyd, Inc. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Invivyd, Inc. Correlación - Moneda/Commodity

0.04
( neutral )

-0.47
( neutral )

0.00
( neutral )

0.59
( weak )

0.00
( neutral )

0.52
( weak )

Invivyd, Inc. Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-2.03M (0.00 %)
EPS:	$-1.810

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-2.03M (0.00 %)
EPS:	$-1.810

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-462 000 (0.00 %)
EPS:	$-2.17

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-5.32

Financial Reports:

No articles found.

Invivyd, Inc.

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.